Stocktoria
LISATA THERAPEUTICS, INC. LSTA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1995-11-03
LISATA THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $0 | — | — | — | — | — | $35.3M |
| R&D expense | — | — | — | — | $17.7M | $9.3M | $10.8M | $7.6M | $15.8M | $16.7M |
| SG&A expense | — | — | $13.0M | $14.1M | $11.5M | $9.9M | $9.3M | $9.4M | $11.8M | $12.8M |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M | -$29.1M | -$19.1M | -$20.1M | -$17.0M | -$27.6M | -$29.5M |
| Interest expense | — | — | — | — | — | — | $0 | $5,000 | $378,000 | $1.8M |
| Income tax | -$962,000 | -$798,000 | -$2.3M | -$2.5M | -$1.5M | -$10.9M | $0 | $0 | -$11.5M | $0 |
| Net income | -$16.6M | -$20.0M | -$20.8M | -$54.2M | -$27.5M | -$8.2M | -$19.4M | -$16.2M | $23.0M | -$32.7M |
| EPS (diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | — | — | $2.56 | $-4.99 |
| Operating cash flow | -$15.9M | -$19.4M | -$20.0M | -$21.2M | -$22.2M | -$8.8M | -$18.9M | -$20.0M | -$20.9M | -$28.2M |
| Free cash flow | -$16.0M | -$19.4M | -$20.0M | -$21.5M | -$22.3M | -$8.8M | -$18.9M | -$20.1M | -$21.0M | -$29.3M |
| Cash & equivalents | $16.0M | $16.2M | $22.6M | $32.2M | $24.6M | $16.5M | $14.0M | $10.3M | $29.2M | $7.1M |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M | $97.0M | $36.0M | $27.2M | $44.6M | $63.4M | $53.5M |
| Total liabilities | $3.1M | $5.7M | $6.8M | $6.7M | $5.0M | $3.8M | $6.6M | $7.1M | $13.2M | $30.0M |
| Shareholders' equity | $14.9M | $29.6M | $48.1M | $66.6M | $92.3M | $32.5M | $20.8M | $37.7M | $50.5M | $4.9M |
Growth · year-over-year · Revenue CAGR -73.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -83.0% | — | — | — | — | — | — | — | — | +56.9% |
| Net income growth | — | — | — | — | — | — | — | -170.4% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.